Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent.

Authors:
Daniel P Cardinali
Daniel P Cardinali
University of Buenos Aires
Argentina

Ann N Y Acad Sci 2005 Dec;1057:327-36

Department of Physiology, Faculty of Medicine, University of Buenos Aires, Argentina.

The circadian time system involves periodic gene expression at the cellular level, synchronized by a hierarchically superior structure located in the hypothalamic suprachiasmatic nuclei. Treatment of circadian rhythm disorders has led to the development of a new type of agent called "chronobiotics," among which melatonin is the prototype. In elderly insomniacs, melatonin treatment decreased sleep latency and increased sleep efficiency, particularly slow-wave sleep. The effect of melatonin on sleep is the consequence of increasing sleep propensity (by augmenting the amplitude of circadian clock oscillation via MT1 receptors) and of synchronizing the circadian clock via MT2 receptors. Daily melatonin production decreases with age and in several pathologies, attaining its lowest values in Alzheimer's disease (AD) patients. About 45% of AD patients have disruptions in their sleep and "sundowning" agitation. Generally, melatonin treatment decreases sundowning in AD patients and reduced variability of sleep onset time. Both open and controlled studies have indicated a significant decrease of cognitive deterioration in AD patients treated with melatonin. The mechanisms accounting for the possible therapeutic effect of melatonin in AD patients may be manifold. On one hand, melatonin treatment promotes slow-wave sleep in the elderly and could be beneficial by augmenting the restorative phases of sleep. On the other hand, melatonin protects neurons against beta-amyloid toxicity. By its combined chronobiotic and cytoprotective properties melatonin provides an innovative neuroprotective strategy to reduce the cost of lifetime treatment of some neuropsychiatric disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1356.025DOI Listing
December 2005
6 Reads

Publication Analysis

Top Keywords

melatonin treatment
12
melatonin
11
sleep
9
chronobiotic cytoprotective
8
slow-wave sleep
8
circadian clock
8
hand melatonin
8
patients
5
treatment
5
patients disruptions
4
sleep "sundowning"
4
disruptions sleep
4
disease patients
4
"sundowning" agitation
4
patients 45%
4
45% patients
4
treatment decreases
4
reduced variability
4
variability sleep
4
sleep onset
4

Similar Publications

The use of chronobiotics in the resynchronization of the sleep-wake cycle.

Cancer Causes Control 2006 May;17(4):601-9

Department of Physiology, Faculty of Medicine, University of Buenos Aires, Paraguay 2155, 1121, Buenos Aires, Argentina.

Treatment of circadian rhythm disorders, whether precipitated by intrinsic factors (e.g., sleep disorders, blindness, mental disorders, aging) or by extrinsic factors (e. Read More

View Article
May 2006

The use of melatonin in Alzheimer's disease.

Neuro Endocrinol Lett 2002 Apr;23 Suppl 1:20-3

Departament of Physiology, Faculty of Medicine, University of Buenos Aires, Argentina.

About 45% of Alzheimer's disease (AD) patients have disruptions in their sleep and sundowning agitation. Since melatonin secretion is greatly inhibited in AD patients we have used melatonin to treat sleep disorders in AD patients since 1995. In a first study [21] we reported, in 7 out of 10 dementia patients treated with melatonin (3 mg p. Read More

View Article
April 2002

Role of melatonin in the regulation of human circadian rhythms and sleep.

J Neuroendocrinol 2003 Apr;15(4):432-7

Center for Chronobiology, Psychiatric University Clinic, Wilhelm Kleinstrasse 27, CH-4025 Basel, Switzerland.

The circadian rhythm of pineal melatonin is the best marker of internal time under low ambient light levels. The endogenous melatonin rhythm exhibits a close association with the endogenous circadian component of the sleep propensity rhythm. This has led to the idea that melatonin is an internal sleep "facilitator" in humans, and therefore useful in the treatment of insomnia and the readjustment of circadian rhythms. Read More

View Article
April 2003

The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease.

Recent Pat Endocr Metab Immune Drug Discov 2011 May;5(2):80-90

Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina.

Treatment of circadian rhythm disorders, whether precipitated by intrinsic factors (e.g., sleep disorders, blindness, mental disorders, aging) or by extrinsic factors (e. Read More

View Article
May 2011